drugset / Trial / NCT02909751

Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer

NCT02909751

Phase 2 Completed 80 enrolled Vejle Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate whether tocotrienol can improve the effect and reduce the side effects of standard chemotherapy before operation for breast cancer.

Timeline

Start
2016-09-14
Primary completion
2019-01-21
Completion
2019-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocotrienol Small molecule 300 mg
Background Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Background Docetaxel Small molecule 100 mg/m2 Intravenous
Background Epirubicin Small molecule 90 mg/m2 Intravenous
Background Paclitaxel Small molecule 80 mg/m2 Intravenous
Background Pertuzumab Monoclonal antibody 420 mg Intravenous
Background Trastuzumab Monoclonal antibody 6 mg/kg Intravenous

Indications